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Abstract
Background: We examined the anti-tumor effect and radiosensitizing potential of a small molecule inhibitor of
fibroblast growth factor receptor (FGFR) in colorectal cancer (CRC) in vitro and in vivo.
Methods: Effects of in vitro drug treatment on cell survival, proliferation, FGFR signaling, cell cycle distribution,
apoptosis and radiosensitivity were assessed using various CRC cell lines with FGFR wild type (Caco2 and
HCA7) and FGFR2 amplification (HCT116, NCI-H716). In vivo tumor responses to FGFR inhibition with and
without radiation therapy were evaluated by growth delay assays in two colorectal xenograft mouse models
(NMRI nu/nu mice injected with NCI-H716 or CaCo2 cells). Mechanistic studies were conducted using Western
blot analysis, immunohistochemistry and qPCR.
Results: In the tested cell lines, the FGFR inhibitor (JNJ-42756493) was effective in vitro and in vivo in CRC
tumors with highest expression of FGFR2 (NCI-H716). In vitro, cell proliferation in this line was decreased,
associated with increased apoptotic death and decreased cell survival. In vivo, growth of NCI-H716 tumors
was delayed by 5 days by drug treatment alone, although when drug delivery was stopped the relative tumor
volume increased compared to control. The FGFR inhibitor did not radiosensitize NCI-H716 tumors either in
vitro or in vivo.
Conclusions: Among tested CRC cell lines, the growth inhibitory activity of this FGFR inhibitor was evident in
cell lines with high constitutive FGFR2 expression, suggesting that FGFR addiction may provide a window for
therapeutic intervention, though caution is advised. Preclinical study with NCI-H716 and Caco2 tumor demonstrated
that continued presence of drug could be essential for tumor growth control, especially in cells with aberrant FGFR
expression. In the tested set-up, the inhibitor showed no radiosensitizing effect.
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Background
The standard treatment for patients with rectal cancer is
chemoradiotherapy followed by surgery, but 30 % of
these patients develop local and distant recurrences [1].
Therefore, an intensification of the preoperative treat-
ment, particularly through the use of molecular targeted
agents, could be beneficial. Fibroblast growth factors
(FGFs) and their receptors are recognized oncogenes
associated with a variety of cancers, including colorectal
cancer (CRC), and are therefore attractive therapeutic
targets.
The mammalian FGF family comprises 18 ligands, which
act through 4 FGFRs (FGFR1, FGFR2, FGFR3 and FGFR4)
[2, 3]. Binding to the receptors causes activation of two
key downstream pathways: the mitogen-activated protein
kinase-extracellular signal-regulated kinase (MAPK-ERK)
and phosphoinositide3-kinase (PI3K)-AKT pathway [3],
which mediate several physiological responses during em-
bryonic development and in the adult organism, including
angiogenesis, tissue repair and hematopoiesis [4].
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Dysregulated expression of many FGFs and all four
FGFRs has been reported in CRC, especially for FGFR2
[5–11]. The effectiveness of FGFR2-targeting therapy for
CRC has been demonstrated in vitro and in vivo illus-
trating the potential of FGFR2 as novel molecular target
for CRC [7].
The effects of FGFR pathway inhibition in combin-
ation with radiotherapy have not been investigated ex-
tensively but inhibition of the cell cycle and angiogenesis
could augment the tumor response [12, 13], as could
drug-induced impairment of DNA repair [14].
The main objective of our study was to mechanistically
evaluate the effects of a pan-FGFR tyrosine kinase in-
hibitor (JNJ-42756493) with and without radiotherapy.
Our hypothesis was first evaluated in vitro in several
established human colorectal cell lines. Since the in vitro
setup does not allow us taking into account the influ-
ence of the tumor-micro environment, the most promis-
ing human colorectal cell lines were in a second step
injected in nude mice (NMRI nu/nu) allowing us to
evaluate the in vivo efficacy of this treatment scheme.
Methods
Cells and cell culture
Several human colorectal cell lines were used: HCT116,
HCA7 (European Collection of Cell Culture, Salisbury,
UK), Caco2 and NCI-H716 (American Type Culture Col-
lection, Manassas, VA, USA). HCT116 cells were main-
tained at 37 °C in a humidified incubator with 5 % carbon
dioxide/95 % air atmosphere in McCoys5A +GlutaMAX
(l-alanyl-l-glutamine), HCA7 in Dulbecco’s Modified
Eagle’s Medium and Caco2 and NCI-H716 cells in RPMI
1640 + GlutaMAX-I medium, all supplemented with
10 % Fetal Bovine Serum (Invitrogen, Carlsbad, Califor-
nia, USA). For HCA7 and Caco2 cells 1 % sodiumpyru-
vate (Invitrogen) was added. Results on HCT116 and
HCA7 cells are in Additional file 1: Figure e1 and
Additional file 2: Figure e2.
FGFR inhibitor
An ATP-competitive small molecule tyrosine kinase in-
hibitor against FGFR1-4 (JNJ-42756493) was provided
by Janssen Pharmaceutica. JNJ-42756493 is a potent,
oral pan-FGFR tyrosine kinase inhibitor with half-
maximal inhibitory concentration values in the low
nanomolar range for all members of the FGFR family
(FGFR1 to FGFR4), with minimal activity on vascular
endothelial growth factor receptor (VEGFR) kinases
compared with FGFR kinases (approximately 20-fold
potency difference) [15]. The drug was dissolved in
dimethylsulfoxide (Sigma, St. Louis, MO, USA) prior to
dilution for in vitro use and in cylodextrin as vehicle
for in vivo experiments. Vehicle controls were used
where appropriate.
Cell viability
The effect of varying drug concentrations on cell growth
and survival was evaluated at 72 h using sulforhodamine
B (SRB) assay for the adherent cells (HCT116, HCA7,
Caco2) [16] and trypan blue dye exclusion for the sus-
pension cells, NCI-H716.
Flow cytometry
Flow cytometry experiments were performed using BD
FACS Canto (Becton Dickinson, Franklin Lakes, NJ,
USA) and analyzed using BD FACS Diva Software.
Cell cycle
After treatment with varying drug doses, for 24 or 72 h,
cells were fixed with 70 % ethanol and stained with
10 μg/ml propidium iodide (Sigma)/100 μg/ml RNaseA
(Invitrogen) solution.
Cell proliferation
Cells were labeled with 75 μM bromodeoxyuridine
(BrdU) (Sigma) and counterstained for DNA with propi-
dium iodide after 24 h drug treatment. Anti-Brdu-FITC
antibody was added (Becton Dickinson, San Jose, CA,
USA) after DNA denaturation with 2 N HCl/Triton x-
100 and neutralization with sodium borate.
Apoptosis
Apoptosis was determined using the Annexin-V-FLUOS
detection kit (Roche, Hague-Road, IN, USA) 72 h after
drug treatment.
Clonogenic assays
Cells were incubated in the presence of drug at various
concentrations. After incubation, cells were irradiated in
suspension with 2, 4 or 6 Gy on a clinical linear acceler-
ator (Varian, Palo Alto, CA, USA) using 6 Mega Volt
photons and seeded in triplicate into 10-cm culture
dishes (Caco2) or diluted into 0.3 % soft agar onto 0.5 %
solidified agar in 10-cm culture dishes (NCI-H716).
After 12 or 21 days incubation for Caco2 and NCI-H716
cells respectively, colonies were fixed and stained with
crystal violet. Colonies (≥50 cells) were counted with
ColCount™ colony counter (Oxford Optronic, Oxford,
UK) and survival fractions were calculated.
Mice
Animal experiments were approved by the animal ethics
committee of the Catholic University Leuven and per-
formed in a licensed A1 laboratory by staff with the re-
quired FELASA certificates taking into account the 3R’s
of the use of animals in research. Since we need immune
deficient mice to develop our xenograft models with
human cell lines, NMRI nu/nu female mice (Janvier,
Saint-Berthevin, France) were used. At the start of the
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experiment, the mice were on average 7 weeks (6–8
weeks) and had an average weight of 29.5 g (22–33).
The mice were housed in individually ventilated cages
with a maximum of 4 mice per cage in a room with a
controlled light/day cycle and controlled temperature.
Sample size calculation
The drug tested in the current proposal will be consid-
ered effective if it can prolong the growth delay of the
tumors with a minimum of 5 days. Taking into account
the effect of 5 days, a standard deviation of 2 days, an α
value of 0.05 and a power of 0.80, the minimal sample
size is three. We divided each treatment group into 2
subgroups; one group to assess the immediate molecular
effects (TP1) and one group for the tumor growth delay
assay (TP2). Therefore, a minimum of 6 mice per group
was included in the experiment. All in vivo experiments
were repeated twice. The data shown in the manuscript
are representative of one of two independent experiments.
Xenograft models
The mice were inoculated in both flanks with 3*106 of
Caco2 or 5*106 of NCI-H716 cells in Matrigel (BD Bio-
sciences, Bedford, MA, USA) subcutaneously in both
flanks. When tumors were on average 100 mm3, the
mice were randomized in 4 treatment groups (control,
radiotherapy, FGFR inhibitor, radiotherapy + FGFR in-
hibitor). Each mice had two tumours (one in each flank)
and the tumours were used as unit for the statistical
analyses. The mice in the different groups were matched
for tumour size to allow a good comparison of the treat-
ment effect in all groups. The characteristics of the mice
can be found in Tables 1 and 2 for the NCI-H716 and
CaCo2 experiment respectively.
Treatment
The FGFR inhibitor was dissolved in cyclodextrin and
administered at a dose of 40 mg/kg as suggested by
Janssen Pharmaceutica. The vehicle used was also cyclo-
dextrin. Both the vehicle and the drugs were adminis-
tered in the morning three times a week for three weeks
by gavage. At the end of the second week (day 12) of
drug treatment, the tumors were irradiated with 5 Gy
(NCI-H716) or 10 Gy (CaCo2) with a Clinical Linear
Accelerator (Varian, Palo Alto, CA, USA) using 16 Mega
electron volt (MeV). During the irradiation, the mice were
anesthetized with Nembutal (CEVA, Brussels, Belgium).
Experimental outcomes
The experimental outcomes included a growth delay
assay to assess the growth inhibiting effect as well as the
radiosensitizing effect of the drug and the assessment of
molecular changes in the tumours after treatment.
Treatment response was evaluated by tumor growth
delay using thrice-weekly caliper measurements. Mice
were sacrificed by cervical dislocation either at the end
of the anti-FGFR treatment (time-point 1 (TP1)) (5
mice/group) or when tumors were >2000 mm3 (time-
point 2 (TP2)) (5–7 mice/group). Thirty minutes before
sacrifice, mice were injected with 60 mg/kg pimonida-
zole (Hypoxyprobe, Burlington, MA, USA). Part of each
tumor was fixed in formalin and embedded in paraffin
for immunohistochemistry and part was snap frozen for
protein and mRNA analyses.
Irradiation
Irradiation was delivered to the cells or tumor site with
a clinical linear accelerator. In vitro, the cells were irra-
diated with 6 MeV photons (dose rate of 2.4Gy/min) for
irradiation of cells in suspension (2, 4, 6Gy). In vivo, the
tumors were irradiated with 16 MeV electrons with a
dose rate of 3Gy/min. For the NCI-H716 xenograft
model, a single dose of 5 Gy was used. Tumors of the
CaCo2 xenograft model were irradiated with a single
dose of 10Gy. The in vitro and in vivo radiation setups
were calculated by the department of Radiation Oncol-
ogy and recalculated on a regular basis.
Gene expression
Quantitative PCR (qPCR) was used to measure copy
numbers for all four FGFRs in cell lines and FGFR2,
FGF1, FGF2, VEGF-A, PlGF, VEGFR1 and VEGFR2 of
mouse and human origin in xenografted tumors. RNA
was isolated by the Qiagen RNeasy Mini Kit (Qiagen,
Table 1 Mice characteristics at start of the treatment experiment (NCI-H716 xenograft model)
Group 1 Group 2 Group 3 Group 4 TOTAL
Number of animals 6 7 7 7 27
Number of tumours 12 14 14 14 54
Weight (g) Mean 30 29 29 29 29
Range 28–33 27–32 28–31 28–31 27–33
Tumour size (mm3) Mean 100 95 97 96 97
Range 26–181 25–165 40–271 39–182 25–271
Treatment given vehicle 5Gy + vehicle FGFR inhibitor FGFR inhibitor + 5 Gy
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Hilden, Germany). RNA was reverse transcribed using
the SuperScript VILO cDNA synthesis Kit (Invitrogen)
followed by qPCR reactions with the Lightcycler 480
(Roche, Mannheim, Germany). Reactions were carried
out on cDNA from cultured cells with Lightcycler 480
Sybr Green I master (Roche) and self-designed primers
(IDT, Coralville, IA, USA). Reactions on cDNA from
tumors were performed with Taqman Fast Universal
PCR Master Mix (Applied Biosystems, Foster city, CA,
USA) using premade probes (Applied Biosystems/IDT)
(Additional file 3: Table e1).
Western blotting
Cell and tumor lysates were prepared in lysis buffer as
described before [17]. Total protein amount was mea-
sured using the Bradford method (Bio-Rad, Hercules,
CA, USA). 10–30 μg of proteins was subjected to electro-
phoresis on NuPage gels (Invitrogen). Immunoblotting
was performed with antibodies recognizing phospho-
FGFR (1:1000), AKT (1:1000), phospho-AKT (1:500),
phospho-ERK (1:500), PARP (1:1000), cleaved PARP
(1:1000), or β-actin (1:1000) from Cell Signaling Technol-
ogy (Beverly, MA) and FGFR2 (1:400) (R&D, Minneapolis,
MN, USA) or ERK2 (1:1000) (Santa Cruz Biotechnology,
Dallas, TX, USA), followed by incubation with the appro-
priate horseradish peroxidase-conjugated secondary anti-
bodies (1:3000) (Cell Signaling; GE Healthcare, Little
Chalfont, UK).
Immunohistochemical staining and analysis
After antigen retrieval and blocking, tumor sections were
incubated overnight at 4 °C with anti-pimonidazole (1/400,
Hypoxyprobe), anti-caspase-3 (ready to use, Biocare Med-
ical) or anti-CD31 (1/200, BC Biosciences); or for 30 min
at room temperature with anti-Ki67 (ready to use, Thermo
Scientific). Appropriate secondary antibodies followed by
3.3’-diaminobenzidine (DAB) substrate (DAKO, Glostrup,
Denmark) were used to visualize antigen presence. Proto-
col details are in Additional file 4: Table e2.
Tumor hypoxic and apoptotic fractions were deter-
mined by the percentage of pimonidazole- and caspase-3
positive cells respectively, the latter using the method of
Going [18]. Ki67 positive nuclei were counted as an
index of proliferation and CD31 used to determine the
number of blood vessels per field for 20 fields per tissue
specimen as a measure of micro vessel density (MVD).
Statistical analysis
Statistical analyses used a one-way analysis of variance
with Tukey’s multiple comparison tests for in vitro com-
parisons and a Mann–Whitney U test for in vivo tumor
growth delay.
For the in vivo experiments, the single tumours were
used as unit of analysis. Immunohistochemical and
qPCR data from in vivo studies were analyzed using a
two-tailed student’s t-test when the data complied with
the conditions of normality and equal variance. Under
other conditions, comparisons were carried out by non-
parametric analysis using the Mann–Whitney rank-sum
test. The Kolmogorov-Smirnov method was used to test
for normality. A significance level of p = 0.05 was used
in all cases. Statistics were calculated using Statistica
software 12 (StatSoft Inc, Tulsa, OK).
Results
Anti-tumor activity in vitro
All four FGFRs were detected by qPCR in all CRC cell
lines in vitro (Fig. 1a). Highest expression, as compared
to the household gene HPRT, was for the FGFR2 gene in
NCI-H716 (48 fold) and Caco2 cells (4 fold) (p < 0.05)
(Fig. 1a). In agreement with these findings, FGFR inhib-
ition significantly decreased cell growth and survival of
NCI-H716 cells at concentrations of ≧ 0.5nM (p < 0.05),
whereas ≧ 5000nM was required for all other cell lines,
including Caco2 (Fig. 1b, Additional file 1: Figure e1A).
In NCI-H716 cells FGFR2 mRNA expression in-
creased in a dose-dependent manner after drug treat-
ment (Additional file 2: Figure e2A) while protein
expression, which was detectable only in this cell line,
decreased (Fig. 1c). Also p-FGFR protein levels de-
creased upon treatment, confirming FGFR inhibition.
No other changes in mRNA or protein expression
were noted in any of the cell lines for any of the
FGFRs (Additional file 2: Figure e2A, Additional file
Table 2 Mice characteristics at start of the treatment experiment (CaCo2 xenograft model)
Group 1 Group 2 Group 3 Group 4 TOTAL
Number of animals 6 6 7 6 25
Number of tumours 12 12 14 12 50
Weight (g) Mean 29 31 29 31 30
Range 22–32 28–33 24–31 29–32 22–33
Tumour size (mm3) Mean 166 168 167 169 168
Range 88–255 79–199 52–259 112–218 52–259
Treatment given vehicle 5Gy + vehicle FGFR inhibitor 5 Gy + FGFR inhibitor
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1: Figure e1B and Fig. 1c). Based on these data, NCI-
H716 and Caco2 cell lines were chosen for further in
vitro and in vivo experimentation.
In vitro effects on cell proliferation, apoptosis and
radiosensitivity
The FGFR inhibitor induced significant changes in
cell cycle distribution, proliferation and apoptosis in
the NCI-H716, but not the Caco2, cell line (Fig. 2).
The G2/M and S subpopulations were significantly
decreased after 24 h incubation with 5nM drug (p <
0.05; Fig. 2a) and this was confirmed by decreased S-
phase BrdU labeling (p < 0.05) (Fig. 2b). The increase
in apoptosis suggested by the changes in the sub-G1
population (Fig. 2a) was confirmed by Annexin-V la-
beling at 0.5nM (p < 0.05) (Fig. 2c). Molecular ana-
lyses by western blotting were consistent with these
findings, with drug-induced PARP cleavage, and inhib-
ition of p-AKT and p-ERK in NCI-H716 but not
Caco2 cells (Fig. 2d). FGFR inhibitor concentrations
that affected FGFR2 receptor expression and cell
growth (Fig. 1) did not significantly affect clonogenic
survival following irradiation of NCI-H716 or Caco2
cells with 2, 4 or 6 Gy (Fig. 3).
Xenograft growth delay
To assess the growth inhibiting effect of the drug, we
compared the relative tumour volumes of xenografted
mice in the control group (group 1) and the group re-
ceiving only the FGFR inhibitor (group 3) (Tables 1 and
2). Relative tumor volume of NCI-H716 tumors was de-
layed by drug treatment by 5 days (p < 0.05), with an in-
crease in volume of on average 24.1 % of pretreatment
values at 1 week (−15.9–92.73 %) while the control
group increased by 88.2 % (−30.3–257.2 %) (p < 0.05)
(Fig. 4). However when drug treatment was stopped, the
relative tumor volume significantly increased between
day 25 and 30 compared to vehicle treatment. The aver-
age increase in tumor volume one week after the end of
drug treatment was 129.4 % (63.9–208.4 %) for the ex-
perimental group and 31.1 % (−25.2–89.1 %) for the
control group (p < 0.05). The data of the CaCo2 experi-
ment are not shown since no significant growth delay
was observed in Caco2 treated tumors. No adverse








Fig. 1 Anti-tumor activity in vitro. a Quantification of FGFR mRNA expression by qPCR. HPRT copy number was used to normalize the data.
Data = means ± SEM of two independent experiments performed in duplicate. b Effect of different concentrations FGFR inhibitor for 72 h
incubation on cell survival. Data = means ± SEM from three independent experiments performed in triplicate. ∗Significantly different from
control conditions at the appropriate drug concentrations (p < 0.05; Tukey). c Immunoblot analysis of FGFR2 after 72 h treatment. β-actin was
used as loading control. Blots shown are representative for one of two independent experiments













Fig. 2 In vitro effect on cell cycle distribution, proliferation and apoptosis. a Cell-cycle distribution of propidium stained cells after 24 (up) and 72 h
(below) drug incubation. b BrdU incorporation after 24 h drug incubation. c Annexin-V detection after 72 h drug incubation. Data = means ± SEM
from three independent experiments performed in triplicate. ∗Significantly different from control conditions (p < 0.05; Tukey). d Immunoblotting
for (cleaved)PARP and downstream signaling molecules after 72 h drug incubation. β-actin served as loading control. Blots shown are representative
for two independent experiments
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Mechanism of action of FGFR inhibition in vivo
Tumors harvested immediately after the end of FGFR
inhibitor treatment (TP1) showed a significant reduction
in proliferation, hypoxia and necrosis as compared to
control tumors (p < 0.05) while apoptosis tended to be
increased, as did MVD (p < 0.05) (Fig. 5a). At later time
points (TP2), these effects disappeared as illustrated by
an increase in proliferation (p < 0.05), hypoxia (N.S.) and
necrosis (p < 0.05) and decrease in MVD (p < 0.05) while
the apoptotic index was unaltered (Fig. 5b).
Western blotting of tumor extracts at TP1 showed a
marked decrease in p-FGFR, p-ERK, and p-AKT in tu-
mors treated with inhibitor (Fig. 5c). Human and murine
VEGF-A and PlGF mRNA expression was also decreased
(p < 0.05) (Fig. 5d). These effects were lost at TP2
(Fig. 5c), when in fact VEGF-A and PlGF mRNA expres-
sion was markedly increased in the drug-treated group
(p < 0.05) (Fig. 5e).
In contrast with the in vitro mRNA expression data,
tumors harvested at TP1 showed reduced human and
murine FGFR2 expression levels as compared to control
tumors (N.S.) (Additional file 2: Figure e2B).
Combination treatment in vivo
To assess the radiosensitizing effect of the drug, the
tumor growth of mice in the treatment group with only
irradiation (group2) were compared with the group re-
ceiving both radiation therapy and the FGFR inhibitor
(group 4) (Tables 1 and 2). While irradiation with 5 Gy
(NCI-H716) or 10 Gy (CaCo2) slowed tumor growth in
both models, the addition of FGFR inhibitor did not
radiosensitize either (Fig. 6a, b). On the other hand ir-
radiation with 5 Gy prevented the relative accelerated
Fig. 3 Radiosensitizing effect in vitro. Radiosensitizing effect of the
indicated concentrations FGFR inhibitor on NCI-H716 (24 h) and
Caco2 (72 h) cells tested by soft agar and colony formation assay,
respectively. Data = means ± SEM of at least three independent





Fig. 4 Anti-tumor activity in vivo. Growth curves of mice bearing NCI-
H716 (a) and Caco2 (b) xenograft tumors (▪). Control tumor-bearing
animals received vehicle (▴). Relative tumor volumes (RTV) are shown.
The line under the graph represents the period of treatment. All
data points are mean ± STDEV of at least 10 tumors per treatment
group. NCI-H716 data are representative of one of two independent
experiments. ∗Significantly different from each other (p < 0.05;
Mann–Whitney U test)
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growth of NCI-H716 tumors following drug withdrawal.
No adverse events were observed in any of the experi-
mental groups.
Immunohistochemistry confirmed the absence of any
drug-radiation interaction. Hypoxia, necrosis and apop-
tosis were the same in the two cohorts. Proliferation at
TP1 showed a small but significant increase in the irradi-
ated group (p < 0.05), while MVD was decreased (p < 0.05)
(Fig. 6c). The effects of irradiation in slowing the regrowth
of drug treated tumors (Fig. 6a), were reflected in a de-
creased proliferation index at TP2 (p < 0.05) (Fig. 6d).
Discussion
Targeting pathways that are dysregulated in cancer
promise to improve tumor control and increase patient
survival, but it is an approach that may generally have to
be combined with conventional cytotoxic therapies like
radiotherapy. Different inhibitors against the FGFR path-
way have been tested as monotherapy or in combination
with other targeted drugs for different cancer types with
promising preclinical and clinical results [19–23]. How-
ever, the radiosensitizing effect of FGFR inhibition has
not been extensively investigated.
In the tested cell lines, this FGFR inhibitor showed po-
tent and selective anti-tumor activity against the cell line
with known FGFR2 amplification (NCI-H716), com-
pared with other cell lines with low/not detected protein
expression of FGFR2 (Caco2, HCT116 and HCA7). The
NCI-H716 cell line displayed high constitutive p-FGFR



















Fig. 5 Reversible in vivo action. NCI-H716 tumors were isolated after drug treatment (TP1) and at the end of the experiment (TP2). a Effect of the
FGFR inhibitor on proliferation, hypoxia, necrosis, apoptosis and micro vessel density (MVD). b Comparison between TP1 and TP2 (= effect drug
cessation). Columns indicate mean ± STDEV of at least 20 tumor sections per treatment group. ∗Significantly different from one another (p < 0.05;
two-tailed student’s t-test). c Western blot for indicated proteins. β-actin served as loading control. Shown blots are from three tumors from different
mice per group. d mRNA expression in isolated tumors at TP1. e Comparison of mRNA expression levels between TP1 and TP2. Data =means ± SEM of
three independent experiments. ∗Significantly different from each other (p < 0.05; two-tailed student’s t-test)
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inhibited by the drug. This is in agreement with other
reports [21, 24–30] and with the first clinical data ob-
tained with this inhibitor [15]. Proliferation of NCI-
H716 cells was abolished, consistent with blockage of
the ERK pathway, followed by dramatic increase in
apoptosis and significant decrease in cell survival, in
agreement with recent published findings where FGFR
inhibition indeed exerted pro-apoptotic effects in vitro
[29, 30]. These events were reflected at the molecular
level by an increase in the apoptotic marker cleaved
PARP and inhibition of the pro-survival AKT pathway.
In agreement with earlier data with other FGFR specific
inhibitors, FGFR inhibition in the NCI-H716 xenograft
model resulted initially in tumor growth delay with de-
creased tumor cell proliferation and inhibition of ERK
activation, which is known to be a major downstream
target of activated FGFRs [20, 30, 31].
However, when the drug was withdrawn, the ratio of
NCI-H716 tumor volume in vivo accelerated dramatic-
ally. This was reflected in an increase in relative prolifer-
ation compared to controls, the magnitude of which
have outstripped angiogenesis as seen in an increase in
the ratio of expression of angiogenic factors, decreased
MVD and increased necrosis. Based on the in vitro ex-
pression data, this relatively accelerated proliferation
may have been due to the fact that drug treatment in-
creased FGFR2 mRNA expression while decreasing
FGFR2 signaling. The pathway may therefore have been
primed cells for accelerated recovery when the drug was
withdrawn. In vivo qPCR data is inconsistent with this
reasoning with a trend showing a decreased FGFR2
mRNA expression in treated tumors. However, tumoral
human FGFR2 expression was much lower than levels
detected in the cell line, which might indicate that stro-
mal cells and necrotic tissue in tumors might dilute the
signals, possibly explaining this contradiction. Very de-
tailed kinetic analyses may be needed to fully evaluate
this hypothesis in absence of any obvious gross effects
on the molecular pathways in this study.
In spite of the major effects of the drug on tumor cell
proliferation and survival, it did not radiosensitize tu-
mors in vitro or in vivo. Several mutually agonistic and
antagonistic factors may be operating in these complex
systems. Cell cycle analysis showed that FGFR inhibition
leads to a decrease of cells in the G2/M phase, being the







Fig. 6 Radiosensitizing effect in vivo. Mice bearing NCI-H716 (a) and Caco2 (b) xenograft tumors were treated with FGFR inhibitor with or without
a single dose of radiotherapy at day 12 of the anti-FGFR treatment (▪ ●). Control tumor-bearing animals received vehicle (▴ x). Relative tumor volumes
(RTV) are shown. The line under the graph represents the period of drug treatment. All data points are mean ± STDEV of at least 10 tumors
per treatment group. NCI-H716 data are representative for one of two independent experiments. c, d Effect of irradiation in treated tumors after drug
treatment (TP1) and at the end of the experiment (TP2). Columns indicate mean ± STDEV of at least 20 tumor sections per treatment group.
∗Significantly different from one another (p < 0.05; two-tailed student’s t-test)
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a decrease in radioresistant S phase cells. The decrease
in tumor proliferation upon FGFR inhibition could ham-
per the efficacy of the radiation. Similar data have been
described by our group with the EGFR inhibitor cetuxi-
mab [33]. It should be noted that even these low doses
of radiation that were used effectively abolished the rela-
tively accelerated proliferation that followed drug with-
drawal. This was associated with effects on tumor cell
proliferation and a decrease in MVD, which may have
been due to the well-known effect of irradiation on
angiogenesis [34]. However it is clear from our in vivo
experiment that in the current set-up the FGFR inhibitor
does not has a radiosensitizing effect in the CRC cell
lines tested. It would be interesting to determine
whether another treatment scheme where FGFR inhib-
ition is started after, and not before, irradiation would be
a more effective therapy by inhibiting angiogenesis and
tumor cell repopulation.
We also have to be aware of some limitations of
the study. In our study we focused only on CRC cell
lines and not on other tumor types, such as endomet-
rial, gastric and breast cancer, were deregulation of
the FGFR pathway has been shown to be implicated
in cancer [3]. Also within our CRC cell lines tested,
only one of them showed aberrant FGFR expression.
Consequently we do not know the effect of the drug
on CRC harboring other FGFR deregulations apart
from FGFR2 overexpression. Furthermore, our in vivo
experiments were performed in mice with a deficient
immune system. Therefore the effect that the immune
system could have in the response to this combined
treatment was not taken into account.
Further research on a larger set of cancer cell lines in
needed. Also combining the drug with other targeted
agents and chemotherapeutics could be interesting.
Conclusions
In summary, the FGFR inhibitor used in this study medi-
ated effective cytotoxicity both in vitro and in vivo, but
only in cells with aberrant FGFR2 expression [35]. These
results underline the dependency of cancer cells upon
oncogenic FGFRs which provides a therapeutic oppor-
tunity for selective intervention by FGFR inhibitors.
Proper patient selection based on FGFR2 status of the
tumor will be critical when testing the inhibitor in future
clinical trials. However, at least for this agent, the con-
tinued presence of drug seems essential and its absence
may cause accelerated tumor regrowth. Based on our
data, this inhibitor does not augment the cytotoxicity of
radiotherapy, but radiotherapy may prevent accelerated
tumor regrowth in CRC cell line. Further investigations
into how best to optimize their delivery with conven-
tional therapies are needed.
Additional files
Additional file 1: Figure e1. Effect on cell survival and protein levels in
HCA7 and HCT116 cells. (A) Effect of different concentrations FGFR
inhibitor for 72 h incubation on cell survival determined by
sulforhodamine B assay. Data = means ± SEM from three independent
experiments performed in triplicate. *Significantly different from control
conditions at the appropriate drug concentrations (p < 0.05; Tukey). (B)
Immunoblot analysis of FGFR2 and downstream signaling molecules after
72 h treatment. β-actin was used as a loading control. Blots shown are
representative for two independent experiments. (PDF 1053 kb)
Additional file 2: Figure e2. Effect on FGFR mRNA levels. (A)
Quantification of FGFR mRNA expression in NCI-H716, Caco2, HCT116
and HCA7 cells after 72 h drug incubation. Data = means ± SEM of
two independent experiments performed in duplicate. (B) Quantification of
FGFR2 mRNA expression in NCI-H716 tumors isolated after drug treatment
(TP1). Data = means ± SEM of three independent experiments. HPRT
copy number was used to normalize the data. *Significantly different
from control conditions at the appropriate drug concentrations (p < 0.05;
Tukey). (PDF 4011 kb)
Additional file 3: Table e1. Primer sequences, primer probes and
cycling conditions used for qPCR of different genes. (DOCX 15 kb)
Additional file 4: Table e2. Specifications antigen retrieval, blocking step
and antibodies used for immunohistochemical staining. (DOCX 15 kb)
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